Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: Cost-effectiveness in France, Germany, Italy, and Spain

Current Medical Research and Opinion

Volumn 26, Issue 1, 2010, Pages 163-175

  Tunis, Sandra L ^a   Willis, William D ^b   Foos, Volker ^a  

^a IQVIA   (United States)

^b Johnson and Johnson   (United Kingdom)

Author keywords

Cost effectiveness; Costs and cost analysis; Diabetes mellitus, type 2; Europe; France; Germany; Healthcare costs; Italy; Self monitoring of blood glucose; Spain

Indexed keywords

HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; COST EFFECTIVENESS ANALYSIS; FEMALE; FRANCE; GERMANY; HEALTH CARE COST; HUMAN; ITALY; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; QUALITY OF LIFE; REIMBURSEMENT; SELF MONITORING; SELF MONITORING OF BLOOD GLUCOSE; SENSITIVITY ANALYSIS; SPAIN; BLOOD; COST BENEFIT ANALYSIS; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; QUALITY ADJUSTED LIFE YEAR;

ADMINISTRATION, ORAL; BLOOD GLUCOSE SELF-MONITORING; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FRANCE; GERMANY; HUMANS; HYPOGLYCEMIC AGENTS; ITALY; QUALITY-ADJUSTED LIFE YEARS; SPAIN;

EID: 77649201837     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903429765     Document Type: Article

References (66)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53 (Pubitemid 38579764)
2. Schnell O, Hummel M, Weber C. Economic and clinical aspects of diabetes regarding self-monitoring of blood glucose. Diabetes Technol Ther 2008; 10:S72-81 (Pubitemid 351725053)
3. Jonsson B. Revealing the cost of type 2 diabetes in Europe. Diabetologia 2002;45:S5-12
4. Wagner EH, Sandhu N, Newton KM, et al. Effect of improved glycemic control on heath care costs and utilization. JAMA 2001;285:182-9 (Pubitemid 32048520)
5. Clarke P, Gray A, Legood R, et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS 65). Diabetes Med 2003;20:442-50 (Pubitemid 36776003)
6. Stratton IM, Adler AL, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes: prospective observational study (UKPDS 35). BMJ 2000;321:405-12 (Pubitemid 30609442)
7. Menzin J, Boulanger L, Langley-Hawthorne C, et al. Potential short-term economic benefits of improved glycemic control. Diabetes Care 2001;24:24-51
8. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
9. Skyler JS, Bergenstal RM, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. Diabetes Care 2009;32:187-92
10. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358: 2545-59
11. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the management of diabetes mellitus. Endocrine Pract 2007;13. Available: http://www.aace.com/pub/pdf/guidelines/DMGuidelines2007.pdf (last accessed 10-30-2009)
12. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004;27:S15-35
13. National Institute for Health and Clinical Excellence (NICE). Type 2 diabetes. The management of type 2 diabetes (update of NICE clinical guidelines E, F, G, and H). 2008 May. http://www.nice.org.uk/guidance/(last accessed 6-30-2009)
14. Palmer A.J., Dinneen S, Gavin III JR, et al. Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes. Curr Med Res Opin 2006;22:861-72 (Pubitemid 43875554)
15. Scherbaum WA, Ohmann C, Abholz HH, et al. Effect of the frequency of self-monitoring of blood glucose in patients with type 2 diabetes treated with oral antidiabetic drugs -a multi-centre, randomized controlled trial. PLoS ONE 2008;3:1-5. Available from: URL: www.plosone.org (last accessed 12-15-2008)
16. Tunis SL, Minshall ME. Self-monitoring of blood glucose in type 2 diabetes: Cost-effectiveness in the United States. Am J Manag Care 2008; 14:131-40 (Pubitemid 351367356)
17. Davis WA, Bruce DG, Davis TM. Is self-monitoring of blood glucose appropriate for all type 2 diabetic patients? The Freemantle Diabetes Study. Diabetes Care 2006;29:1764-70 (Pubitemid 44156627)
18. Davis WA, Bruce DG, Davis TM. Does self-monitoring of blood glucose improve outcome in type 2 diabetes? The Fremantle Diabetes Study. Diabetologia 2007;50:510-55
19. Barnett AH, Krentz AJ, Strojek K, et al. The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study). Diabetes Obes Metab 2008;10:1239-47
20. Guerci B, Drouin P, Grange V, et al. Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study. Diabetes Metab 2003; 29:587-94 (Pubitemid 38082160)
21. Muchmore DB, Springer J, Miller M. Self-monitoring of blood glucose in overweight type 2 diabetic patients. Acta Diabetol 1994;31:215-19
22. Schwedes U, Siebolds M, Mertes G, Group SS. Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients. Diabetes Care 2002;25: 1928-32 (Pubitemid 41071046)
23. Karter AJ, Parker MM, Moffet HH, et al. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care 2006;29: 1757-63 (Pubitemid 44156626)
24. Martin S, Schneider B, Heinemann L, et al. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia 2006;49:271-8 (Pubitemid 43185395)
25. Murata GH, Shah JH, Hoffman RM, et al. Intensified blood glucose monitoring improves glycemic control in stable, insulin-treated veterans with type 2 diabetes: The Diabetes Outcomes in Veterans Study (DOVES). Diabetes Care 2003;26:1759-63 (Pubitemid 36929116)
26. O'Kane MJ, Bunting B, Copeland M, Coates VE. Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial. BMJ 2008;386:1174-7 (Pubitemid 351809278)
27. Davidson MB, Castellanos M, Kain D, Duran P. The effect of self monitoring of blood glucose concentrations on glycated hemoglobin levels in diabetic patients not taking insulin: a blinded, randomized trial. Am J Med 2005; 118:422-5 (Pubitemid 40461003)
28. Farmer A, Wade A, Goyder E, et al. Impact of self-monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ 2007;335:132-9
29. Schutt M, Kern W, Krause U, et al. Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria. Exp Clin Endocrinol Diabetes 2006;114:384-8 (Pubitemid 44265571)
30. Weber C, Neeser K, Schneider B, et al. Self-measurement of blood glucose in patients with type 2 diabetes: a health economic assessment. J Diabetes Sci Technol 2007;1:676-84
31. Simon J, Gray A, Clarke P, et al. Cost-effectiveness of self-monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM Trial. BMJ 2008;336:1177-80 (Pubitemid 351809279)
32. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision making. Curr Med Res Opin 2004;20:S5-26
33. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004; 20:S27-40 (Pubitemid 39349906)
34. American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:2262-5
35. The UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-53
36. Stevens RJ, Stratton IM, Holman RR. Modeling glucose exposure as a risk factor for photocoagulation in type 2 diabetes (UKPDS 58). J Diabetes Complic 2002;16:371-6 (Pubitemid 35449080)
37. Kothari V, Stevens RJ, Adler AI, et al. Risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine (UKPDS 60). Stroke 2002;33:1776-81 (Pubitemid 34761059)
38. Stratton IM, Kohner EM, Aldington SJ, et al. Risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis (UKPDS 50). Diabetologia 2001;44:156-63 (Pubitemid 32156199)
39. Karter AJ, Ackerson LM, Darbinian JA, et al. Self-monitoring of blood glucose levels and glycemic control: The Northern California Kaiser Permanente Diabetes Registry. Am J Med 2001;111:1-9 (Pubitemid 32635255)
40. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey (NHANES) 1999-2000 Dataset: Diabetes Survey. US Department of Health and Human Services, Hyattsville, MD, 2000. Available: http://www.cdc.gov/nchs/data/nhanes/ spq-di.pdf (last accessed 3-3-2008)
41. Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000;23:754-8 (Pubitemid 30414188)
42. Braändle M, Zhou H, Smith BRK, et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003;26:2300-4 (Pubitemid 36993316)
43. Klein R, Klein BEK. Vision disorders in diabetes. In: Harris MI, Cowie CC, Stern MP, eds. Diabetes in America, 2nd edn. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health; 1995. Report number 95-1468. Available: http://diabetes.niddk. nih.gov/dm/pubs/america/contents.htm (last accessed 7-7-2007)
44. Moss SE, Klein R, Klein BE. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med 1992;152:610-16
45. Ray JA, Valentine WJ, Secnik K, et al. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr Med Res Opin 2005;21:1617-29 (Pubitemid 41505028)
46. ISPOR Global Health Care Systems Road Map. Reimbursement Processes Around the World. ISPOR Website 2008 October 1; http://www.ispor.org/HTARoadMaps (last accessed 8-29-2009)
47. Institute for Quality and Efficiency in Heath Care. Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System. March 16, 2009. http://www.iqwig.de/index.en.html (last accessed 8-24-2009)
48. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002; 22:340-9 (Pubitemid 34791321)
49. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583-637
50. Begg S, Vos T, Barker B, et al. The Burden of Disease and Injury in Australia 2003. Australian Institute of Health and Welfare, 2007. Available: http://www.aihw.gov.au/publications/index.cfm/title/10317 (last accessed 3-3-2008)
51. Carrington AL, Mawdsley SK, Morley M, et al. Psychological status of diabetic people with or without lower limb disability. Diabetes Res Clin Pract 1996; 32:19-25 (Pubitemid 26191382)
52. National Institute for Health and Clinical Excellence (NICE). Guidance on the use of long-acting insulin analogues for the treatment of diabetes-insulin glargine, Technology Appraisal Guidance Report No. 53, 2002. Available: http://www.nice/org.uk/nicemedia/pdf/53 (last accessed 4-20-2008)
53. Halpern EF, Weinstein MC, Hunink MG, et al. Representing both first-and second-order uncertainties by Monte Carlo simulation for groups of patients. Med Decis Making 2000;20:314-22 (Pubitemid 30470727)
54. Briggs A, Wonderling D, Mooney C. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40 (Pubitemid 27384638)
55. Bergenstal RM, Gavin III JR. The role of self-monitoring of blood glucose in the care of people with diabetes: report of a global consensus conference. Am J Med 2006;118:1-6S
56. Klonoff DC, Bergenstal RM, Blonde L, et al. Consensus report of the coalition for clinical research-self-monitoring of blood glucose. J Diabetes Sci Tech 2008;2:1030-52
57. International Diabetes Federation. Global Guidelines for Type 2 Diabetes. 2005. http://www.idf.org/Global guideline (last accessed 7-11-2009)
58. Claxton K, Buxton MJ, Culyer A, et al. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 2008;336:251-4 (Pubitemid 351251624)
59. Klonoff DC. New evidence demonstrates that self-monitoring of blood glucose does not improve outcomes in type 2 diabetes-when the practice is not applied properly. J Diabetes Sci Technol 2008;2:342-8
60. Schnell O, Heinemann L. Self-monitoring of blood glucose in noninsulintreated patients with type 2 diabetes: a never ending story? J Diabetes Sci Technol 2007;1:614-16
61. Nielsen JK, Christiansen JS. Self-monitoring of blood glucose-epidemiological and practical aspects. Diabetes Technol Ther 2008;10:S35-42 (Pubitemid 351725048)
62. Canadian Optimal Medication Prescribing and Utilization Service (COMPUS). Cost-effectiveness of blood glucose test strips in the management of adult patients with diabetes mellitus. Canadian Agency for Drugs and Technologies in Health (CADTH); 2009 Mar 1. http://www.cadth.ca/media/pdf/BGTS-Consolidated- Economic-Report.pdf (last accessed 9-3-2009)
63. Goyder E. Should we stop patients with non-insulin treated diabetes using self-monitoring of blood glucose? The implications of the Diabetes Glycaemic Education and Monitoring (DiGEM) trial. Prim Care Diabetes 2008;2:91-3
64. Soumerai S, Mah C, Zhang F, et al. Effects of health maintenance organization of self-monitoring devices on diabetes self-care and glycemic control. Arch Intern Med 2004;164:645-52 (Pubitemid 38392979)
65. McEwan PC, Chamberlain GH, Griffin AD. Association between self monitoring of blood glucose and HbA1c in UK primary care. Poster presented at Diabetes UK Annual Professional Conference, Glasgow, Scotland, 11-13 March, 2009
66. O'Sullivan A, Thompson D. Country-to-country adaptation of pharmacoeconomic research: methodologic challenges and potential solutions. ISPOR Connections, Jan-Feb, 2009